Ellis George LLP: CA Court of Appeal Upholds $5 Million Jury Verdict Against Bristol-Meyers-Squibb-owned Impact Biomedicines
Dr. Brewer, chair of the neurology department at UC San Diego, was represented by Christopher W. Arledge and Courtney L. Mitchell, both of Ellis George LLP, and Peter Afrasiabi of One LLP.
At trial in the San Diego County Superior Court, a 12-member jury awarded Dr. Brewer more than $5 million, finding that Impact Biomedicines and Dr. Hood had defrauded Dr. Brewer as part of Impact Biomedicines' effort to end an FDA-mandated clinical hold and get Impact Biomedicines' experimental cancer drug approved. The jury accepted Dr. Brewer's argument that Impact Biomedicines and Dr. Hood had misled the FDA about the work Dr. Brewer had done for them and the conclusions he had reached and then concealed its false statements to the FDA from Dr. Brewer.
Later, the trial court agreed that Dr. Brewer had proven his fraud case but reduced the damages number significantly. At the time, Mr. Arledge said he disagreed with the court's decision to reduce the damages and predicted that the trial court's order would be reversed on appeal. Today it was. According to the Court of Appeal's opinion, 'We conclude that substantial evidence supports the jury's findings on liability and damages, and the jury's award of punitive damages was not constitutionally excessive…'
'This was a hard-fought win against a very well-funded opponent and one of the largest, most-prestigious law firms in the country. Now a jury, a trial court, and an appellate court have all agreed that Dr. Brewer proved his fraud claim, and we're grateful to the Court of Appeal for recognizing that the trial court's reduction in Dr. Brewer's damages was a legal error,' said Mr. Arledge. 'This is an important win for Dr. Brewer and for patients who must be able to rely on the FDA drug-approval process.'
Impact Biomedicines was represented by Colleen C. Smith, John T. Ryan, Andrew R. Gray, and Melissa Arbus Sherry, all of Latham & Watkins.
James Brewer v Impact Biomedicines, et al. Superior Court No. 37-2019-00067876-CU-CO-CTL
About Ellis George LLP
Ellis George LLP is an elite litigation and trial firm based in Los Angeles and with offices in San Francisco and New York. Whether plaintiff or defendant, individual, Fortune 500 corporation or entrepreneur, clients call upon Ellis George when seeking litigation counsel of the highest quality, creativity, dedication, and ethics. Visit www.ellisgeorge.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
20 minutes ago
- Business Insider
FDA investigating death of child who received Sarepta's Elevidys
The U.S. FDA is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne muscular dystrophy. The death occurred on June 7, 2025. The FDA has requested and received voluntary suspension of product distribution as it investigates the safety concerns. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
Married couple whose home was bursting with truckloads of illegal sex pills sentenced
A married couple from New York has been sentenced after federal agents confiscated truckloads of illegal sex pills from their home. Eduard Yusupov and Diana Fuzailov sold male and female sexual enhancement products online via their company Love Potion, Inc., claiming them to be made from natural ingredients. But the products offered by the couple included erectile dysfunction drugs containing an undeclared ingredient: Sildenafil – the active ingredient in Viagra, according to court documents seen by The Independent. Love Potion's online advertising falsely claimed the drugs and dietary supplements, which were largely manufactured in China, were approved by the U.S. Food and Drug Administration. This was not true, as Sildenafil must be sold via prescription. Between November 2016 and February 2022, the couple received 200 parcels of sex pills to their home in Wading River, New York, before selling and shipping the products to customers located throughout the U.S. Two such parcels were seized by customs officials in March 2021 and contained more than 20,000 capsules. The powder inside the capsules contained Sildenafil. According to court documents, the couples' earnings from the scheme totaled over $3.5 million. Yusupov and Fuzailov pleaded guilty to charges of wire fraud and introducing misbranded drugs into interstate commerce and were sentenced at a federal court on Long Island Thursday. Judge Joanna Seybert sentenced Yusupov to a year and a day in prison and Fuzailov received three years of probation, according to The New York Times. According to the FDA, 'contaminating' drugs with undeclared substances constitutes a type of medical health fraud. 'Many products that claim to help with sexual enhancement or treat sexual dysfunction—such as male enhancement supplements, erectile dysfunction treatments, male energy pills and stamina pills—are likely to be contaminated with dangerous hidden ingredients,' the FDA website states. 'These contaminated products are a type of medication health fraud.' Addressing the judge Thursday, Yusupov admitted to being '100 percent at fault' and said he was 'addicted' to buying the pills, The NYT reported. In a letter to the judge prior to her sentencing, Fuzailov's lawyers wrote she had accepted her part in the crime and was remorseful for her actions. 'She did not set out to commit a crime or do anything illegal.' the letter said. 'It is also acknowledged that she did not properly vet what she and her husband were doing and instead focused on making money without properly investigating the basis for the business. 'She also acknowledges that the lure of making money and paying off their debts took precedence over the red flags she increasingly became aware of.'
Yahoo
4 hours ago
- Yahoo
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass., July 25, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement* Death was reported to health authorities* Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking StatementsThis statement contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. View source version on Contacts Investor Contact: Ian Estepan617-274-4052iestepan@ Media Contacts: Tracy Sorrentino617-301-8566tsorrentino@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
